Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

DAVID I BERNSTEIN

Allopathic & Osteopathic Physicians Allergy & Immunology

NPI
1558369843
CMS profile
1204555
Location
CINCINNATI, OH

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$7,415.56

55 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

Nature of paymentAmountRecords
Consulting Fee $4,225.00 3
Honoraria $2,200.00 2
Food and Beverage $990.56 50

By paying entity

PY2021 · entire year · sorted by reported total

Page 2 of 2; records 51–55 of 55 matching records. This page contains 5 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

DAVID I BERNSTEIN

NPI 1558369843 · CMS profile ID 1204555

Allopathic & Osteopathic Physicians / Allergy & Immunology

CINCINNATI, OH

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–55 of 55 matching records. This page contains 5 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1558369843?year=2021&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
DAVID I BERNSTEIN, NPI 1558369843, CMS profile ID 1204555. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–55 of 55 matching records. This page contains 5 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1558369843?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). DAVID I BERNSTEIN, NPI 1558369843, CMS profile ID 1204555. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–55 of 55 matching records. This page contains 5 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1558369843?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
DAVID I BERNSTEIN, NPI 1558369843, CMS profile ID 1204555, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–55 of 55 matching records. This page contains 5 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1558369843?year=2021&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

55 matching records · $7,415.56 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 55 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–55 of 55.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
ALK-Abello, Inc $15.3802/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 809201567 CMS
ALK-Abello, Inc $21.9601/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 809201571 CMS
AstraZeneca Pharmaceuticals LP $14.5001/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829476267 CMS
Novartis Pharmaceuticals Corporation $23.5001/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 812608117 CMS
BioCryst US Sales Co., LLC $22.2401/06/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 849114477 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $50,166.27 80
PY2020 $13,781.18 38
PY2021 $7,415.56 55
PY2022 $10,237.38 64
PY2023 $3,548.05 63
PY2024 $4,621.65 46
PY2025 $3,209.40 40

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $405,095.30 54
PY2024 Principal investigator $328,202.37 88
PY2023 Principal investigator $343,960.50 84
PY2022 Recipient $19,531.12 5
PY2022 Principal investigator $259,732.42 95
PY2021 Principal investigator $233,063.44 104
PY2020 Principal investigator $294,189.91 92
PY2019 Recipient $1,560.34 8
PY2019 Principal investigator $766,480.31 159

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

54 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $4,125.60 12/11/2025 Non-covered Recipient Entity
Bernstein Clinical Research Center, Inc.
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244047714
Principal investigator 1 GlaxoSmithKline, LLC. $1,562.00 11/24/2025 Non-covered Recipient Entity
BERNSTEIN CLINICAL RESEARCH CENTER LLC
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192099255
Principal investigator 1 GlaxoSmithKline, LLC. $2,980.00 11/24/2025 Non-covered Recipient Entity
BERNSTEIN CLINICAL RESEARCH CENTER LLC
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192186004
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $4,284.90 11/20/2025 Non-covered Recipient Entity
Bernstein Clinical Research Center, Inc.
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244047712
Principal investigator 1 AstraZeneca Pharmaceuticals LP $2,500.00 10/22/2025 Non-covered Recipient Entity
BERNSTEIN CLINICAL RESEARCH
A Randomized Double Blind Double Dummy Parallel Group Multicenter 24 to 52 Week Variable Length Study to Assess the Efficacy and Safety of Budesonide Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler No dispute reported 06/30/2026 1185543104
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $2,222.10 10/14/2025 Non-covered Recipient Entity
Bernstein Clinical Research Center, Inc.
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244047710
Principal investigator 1 GlaxoSmithKline, LLC. $5,090.00 10/02/2025 Non-covered Recipient Entity
BERNSTEIN CLINICAL RESEARCH CENTER LLC
A MULTI-CENTRE, SINGLE ARM, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE No dispute reported 06/30/2026 1192144904
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $2,732.40 09/17/2025 Non-covered Recipient Entity
Bernstein Clinical Research Center, Inc.
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244047708
Principal investigator 1 GlaxoSmithKline, LLC. $764.75 09/08/2025 Non-covered Recipient Entity
BERNSTEIN CLINICAL RESEARCH CENTER LLC
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192186739
Principal investigator 1 GlaxoSmithKline, LLC. $2,500.00 08/20/2025 Non-covered Recipient Entity
BERNSTEIN CLINICAL RESEARCH CENTER LLC
A MULTI-CENTRE, SINGLE ARM, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE No dispute reported 06/30/2026 1192186009
Principal investigator 1 GlaxoSmithKline, LLC. $3,940.00 08/20/2025 Non-covered Recipient Entity
BERNSTEIN CLINICAL RESEARCH CENTER LLC
A MULTI-CENTRE, SINGLE ARM, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE No dispute reported 06/30/2026 1192186646
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $3,242.70 08/19/2025 Non-covered Recipient Entity
Bernstein Clinical Research Center, Inc.
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244047706
Principal investigator 1 SANOFI US SERVICES INC. $2,500.00 08/11/2025 Non-covered Recipient Entity
Bernstein Clinical Research Center Llc
Randomized, Double-blind, Placebo-controlled, Parallel Group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) No dispute reported 06/30/2026 1226084373
Principal investigator 1 GlaxoSmithKline, LLC. $102.03 08/01/2025 Non-covered Recipient Entity
BERNSTEIN CLINICAL RESEARCH CENTER LLC
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192186625
Principal investigator 1 GlaxoSmithKline, LLC. $500.00 08/01/2025 Non-covered Recipient Entity
BERNSTEIN CLINICAL RESEARCH CENTER LLC
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192186735
Principal investigator 1 GlaxoSmithKline, LLC. $2,233.49 07/25/2025 Non-covered Recipient Entity
BERNSTEIN CLINICAL RESEARCH CENTER LLC
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192186000
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $3,242.70 07/24/2025 Non-covered Recipient Entity
Bernstein Clinical Research Center, Inc.
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244047704
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $7,176.60 06/24/2025 Non-covered Recipient Entity
Bernstein Clinical Research Center, Inc.
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244047702
Principal investigator 1 AstraZeneca Pharmaceuticals LP $10,468.30 06/23/2025 Non-covered Recipient Entity
BERNSTEIN CLINICAL RESEARCH
A 24-Week Efficacy and Safety Study to Assess Budesonide and Formoterol Fumarate Metered Dose Inhaler in Adult and Adolescent Participants With Inadequately Controlled Asthma No dispute reported 06/30/2026 1185543102
Principal investigator 1 GlaxoSmithKline, LLC. $894.90 06/16/2025 Non-covered Recipient Entity
BERNSTEIN CLINICAL RESEARCH CENTER LLC
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192186748
Principal investigator 1 GlaxoSmithKline, LLC. $100.76 05/16/2025 Non-covered Recipient Entity
BERNSTEIN CLINICAL RESEARCH CENTER LLC
A MULTI-CENTRE, SINGLE ARM, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE No dispute reported 06/30/2026 1192186641
Principal investigator 1 PFIZER INC. $134,945.83 05/12/2025 Covered Recipient Teaching Hospital
CHILDRENS HOSPITAL MEDICAL CENTER
CHARACTERIZATION OF HSV INHIBITORS IN THE HSV2 GUINEA PIG MODEL OF INFECTION No dispute reported 06/30/2026 1228771320
Principal investigator 1 SANOFI US SERVICES INC. $1,300.00 05/12/2025 Non-covered Recipient Entity
Bernstein Clinical Research Center Llc
Randomized, Double-blind, Placebo-controlled, Parallel Group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) No dispute reported 06/30/2026 1226084331
Principal investigator 1 GlaxoSmithKline, LLC. $76.50 05/07/2025 Non-covered Recipient Entity
BERNSTEIN CLINICAL RESEARCH CENTER LLC
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192099249
Principal investigator 1 GlaxoSmithKline, LLC. $100.00 05/07/2025 Non-covered Recipient Entity
BERNSTEIN CLINICAL RESEARCH CENTER LLC
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192185993
Principal investigator 1 GlaxoSmithKline, LLC. $2,359.80 05/05/2025 Non-covered Recipient Entity
BERNSTEIN CLINICAL RESEARCH CENTER LLC
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192186723
Principal investigator 1 GlaxoSmithKline, LLC. $25.50 05/02/2025 Non-covered Recipient Entity
BERNSTEIN CLINICAL RESEARCH CENTER LLC
A MULTI-CENTRE, SINGLE ARM, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE No dispute reported 06/30/2026 1192186621
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $5,464.80 04/24/2025 Non-covered Recipient Entity
Bernstein Clinical Research Center, Inc.
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244047698
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,020.60 04/24/2025 Non-covered Recipient Entity
Bernstein Clinical Research Center, Inc.
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244047700
Principal investigator 1 GlaxoSmithKline, LLC. $100.76 04/23/2025 Non-covered Recipient Entity
BERNSTEIN CLINICAL RESEARCH CENTER LLC
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192144895
Principal investigator 1 GlaxoSmithKline, LLC. $3,000.00 04/23/2025 Non-covered Recipient Entity
BERNSTEIN CLINICAL RESEARCH CENTER LLC
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192144899
Principal investigator 1 GlaxoSmithKline, LLC. $100.76 04/23/2025 Non-covered Recipient Entity
BERNSTEIN CLINICAL RESEARCH CENTER LLC
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192185978
Principal investigator 1 GlaxoSmithKline, LLC. $300.00 04/23/2025 Non-covered Recipient Entity
BERNSTEIN CLINICAL RESEARCH CENTER LLC
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192185997
Principal investigator 1 GlaxoSmithKline, LLC. $31.60 04/14/2025 Non-covered Recipient Entity
BERNSTEIN CLINICAL RESEARCH CENTER LLC
A MULTI-CENTRE, SINGLE ARM, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE No dispute reported 06/30/2026 1192144908
Principal investigator 1 GlaxoSmithKline, LLC. $428.00 04/14/2025 Non-covered Recipient Entity
BERNSTEIN CLINICAL RESEARCH CENTER LLC
A MULTI-CENTRE, SINGLE ARM, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE No dispute reported 06/30/2026 1192186637
Principal investigator 1 GlaxoSmithKline, LLC. $696.00 04/09/2025 Non-covered Recipient Entity
BERNSTEIN CLINICAL RESEARCH CENTER LLC
A MULTI-CENTRE, SINGLE ARM, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE No dispute reported 06/30/2026 1192144890
Principal investigator 1 GlaxoSmithKline, LLC. $3,000.00 04/09/2025 Non-covered Recipient Entity
BERNSTEIN CLINICAL RESEARCH CENTER LLC
A MULTI-CENTRE, SINGLE ARM, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE No dispute reported 06/30/2026 1192144913
Principal investigator 1 GlaxoSmithKline, LLC. $350.00 04/09/2025 Non-covered Recipient Entity
BERNSTEIN CLINICAL RESEARCH CENTER LLC
A MULTI-CENTRE, SINGLE ARM, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE No dispute reported 06/30/2026 1192186629
Principal investigator 1 GlaxoSmithKline, LLC. $38.60 04/09/2025 Non-covered Recipient Entity
BERNSTEIN CLINICAL RESEARCH CENTER LLC
A MULTI-CENTRE, SINGLE ARM, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE No dispute reported 06/30/2026 1192186633
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $75.00 03/13/2025 Non-covered Recipient Entity
Bernstein Clinical Research Center, Inc.
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244047696
Principal investigator 1 GlaxoSmithKline, LLC. $1,033.00 03/07/2025 Non-covered Recipient Entity
BERNSTEIN CLINICAL RESEARCH CENTER LLC
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192186617
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $9,850.95 02/27/2025 Non-covered Recipient Entity
Bernstein Clinical Research Center, Inc.
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244047694
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $204.60 02/25/2025 Non-covered Recipient Entity
Bernstein Clinical Research Center, Inc.
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244047718
Principal investigator 1 GlaxoSmithKline, LLC. $2,549.80 02/21/2025 Non-covered Recipient Entity
BERNSTEIN CLINICAL RESEARCH CENTER LLC
A MULTI-CENTRE, SINGLE ARM, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE No dispute reported 06/30/2026 1192186728
Principal investigator 1 GlaxoSmithKline, LLC. $2,014.00 02/07/2025 Non-covered Recipient Entity
BERNSTEIN CLINICAL RESEARCH CENTER LLC
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192185984
Principal investigator 1 GlaxoSmithKline, LLC. $1,106.00 02/07/2025 Non-covered Recipient Entity
BERNSTEIN CLINICAL RESEARCH CENTER LLC
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192186743
Principal investigator 1 GlaxoSmithKline, LLC. $942.00 02/07/2025 Non-covered Recipient Entity
BERNSTEIN CLINICAL RESEARCH CENTER LLC
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192186752
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $3,310.20 01/30/2025 Non-covered Recipient Entity
Bernstein Clinical Research Center, Inc.
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244047692
Principal investigator 1 Amgen Inc. $22,954.49 01/27/2025 Non-covered Recipient Entity
BERNSTEIN CLINICAL RESEARCH CENTER LLC
A Phase 2, Randomized, Double-blind, Placebo-controlled, Dose Ranging Study to Assess the Efficacy and Safety of Rocatinlimab in Adult Subjects With Moderate-to-severe Asthma No dispute reported 06/30/2026 1246639597
Principal investigator 1 GlaxoSmithKline, LLC. $3,516.90 01/22/2025 Non-covered Recipient Entity
BERNSTEIN CLINICAL RESEARCH CENTER LLC
A MULTI-CENTRE, SINGLE ARM, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE No dispute reported 06/30/2026 1192185988
Principal investigator 1 AstraZeneca Pharmaceuticals LP $94,123.79 01/03/2025 Non-covered Recipient Entity
BERNSTEIN CLINICAL RESEARCH
A Randomized, Placebo-controlled, Double-blind, Multicenter, 12 Week, 3-Way, Partial-replicate Crossover Pharmacodynamic Study to Assess the Equivalence of Budesonide and Albuterol (BDA) Delivered by MDI HFO Compared with BDA Delivered by MDI HFA in Participants with Asthma No dispute reported 06/30/2026 1185543106
Principal investigator 1 Eli Lilly and Company $46,362.59 01/03/2025 Non-covered Recipient Entity
BERNSTEIN CLINICAL RESEARCH CENTER LLC
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LEBRIKIZUMAB/ LY3650150 IN ADULT PARTICIPANTS WITH PERENNIAL ALLERGIC RHINITIS No dispute reported 06/30/2026 1187876399
Principal investigator 1 GlaxoSmithKline, LLC. $200.00 01/03/2025 Non-covered Recipient Entity
BERNSTEIN CLINICAL RESEARCH CENTER LLC
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192144917
Principal investigator 1 GlaxoSmithKline, LLC. $350.00 01/03/2025 Non-covered Recipient Entity
BERNSTEIN CLINICAL RESEARCH CENTER LLC
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192186732